Obstetrics and Gynecology
Nahla W. Shady; Amed A. Taha; Hany F. Sallam
Volume 8, Issue 6 , November and December 2023, , Pages 579-586
Abstract
Background & Objective: To determine the safety and adequacy of intravenous (IV) carbetocin compared to IV tranexamic acid (TA) plus sublingual misoprostol in reducing hemorrhage during and following cesarean delivery (CD) in women with at least one risk factor for postpartum hemorrhage.Materials ...
Read More
Background & Objective: To determine the safety and adequacy of intravenous (IV) carbetocin compared to IV tranexamic acid (TA) plus sublingual misoprostol in reducing hemorrhage during and following cesarean delivery (CD) in women with at least one risk factor for postpartum hemorrhage.Materials & Methods: This clinical study was randomized. We randomly assigned 400 term pregnant women who were candidates for elective CD to receive either a 100 μg intravenous infusion of carbetocin or 1gm. IV TA along with 400 μg of sublingual misoprostol after delivery. Comparing the quantity of blood loss at and six hours following a CD was the primary result. We also disclosed the necessity for any extra medications and any adverse drug reactions.Results: When compared to the misoprostol plus tranexamic acid group, the carbetocin group's total mean blood loss was considerably higher (829.7 293.3 mL vs. 609.33 211.5 mL; P = 0.0001). Following the administration of carbetocin and misoprostol with TA, respectively, 9.5% and 26.5% of patients required further uterotonics treatment (P = 0.0001). When compared to the carbetocin group, the misoprostol group's side effects, such as a bad taste in the mouth and fever, were much greater (P = 0.0001).Conclusion: When it comes to minimizing overall blood loss during and after CD, IV tranexamic acid combined with sublingual misoprostol is superior to IV carbetocin.
Obstetrics and Gynecology
Fariba Almassinokiani; Mahzad Alimian; Parinaz Hamednasimi
Volume 8, Issue 3 , May and June 2023, , Pages 210-216
Abstract
Background & Objective: Hysterectomy is the most common gynecological surgery. Every year, numerous women around the world undergo this type of surgery for various reasons. Regardless of the type of surgery, bleeding during surgery and after surgery is the most common consequence? Tranexamic ...
Read More
Background & Objective: Hysterectomy is the most common gynecological surgery. Every year, numerous women around the world undergo this type of surgery for various reasons. Regardless of the type of surgery, bleeding during surgery and after surgery is the most common consequence? Tranexamic acid is a cheap, available and low-complication drug that has been considered in recent years to control bleeding. The present study investigated the effectiveness of Tranexamic acid on the bleeding during laparotomy hysterectomy in women aged 35 to 55 years.Materials & Methods: This study was a randomized, double-blind clinical trial performed on 80 patients undergoing laparotomy hysterectomy. Using a random number table, patients were divided into two groups A (receiving Transid) and the other group receiving drug B (not receiving Transid), both of which received 100 ml of normal saline prepared to reduce bias in the prepared syringe.Results: Mean age of the patients was 46.24 ± 5.21 years. Based on the results of mean hemoglobin before surgery, the rate of infection, infusion and induction in the control and intervention groups were not statistically different (P > 0.05). Also, the mean hemoglobin variables before and after hemorrhage were estimated by the surgeon and hemorrhage estimated according to Hernandez formula were not statistically different in the two groups (P > 0.05).Conclusion: Tranexamic acid administration has no effect on the amount of bleeding during hysterectomy laparotomy.